Hiroaki Ozasa

1.7k total citations
80 papers, 1.1k citations indexed

About

Hiroaki Ozasa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hiroaki Ozasa has authored 80 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Hiroaki Ozasa's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (22 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Hiroaki Ozasa is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (22 papers) and Cancer Immunotherapy and Biomarkers (16 papers). Hiroaki Ozasa collaborates with scholars based in Japan, United States and Tunisia. Hiroaki Ozasa's co-authors include Tetsuya Oguri, Ken Maeno, Shigeki Sato, Ryuzo Ueda, Yuichi Sakamori, Young Hak Kim, Mikinori Miyazaki, Hironori Yoshida, Hiroki Nagai and Toyohiro Hirai and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hiroaki Ozasa

68 papers receiving 1.1k citations

Peers

Hiroaki Ozasa
Chung-Tsen Hsueh United States
Fraser Symmans United States
Ken Suzawa Japan
Ichiro Kawada Japan
Shigebumi Tanaka Japan
Jianchun Duan China
Judit Moldvay Hungary
Mark C. Markowski United States
Angela Listì Italy
Jingyu Yu United States
Chung-Tsen Hsueh United States
Hiroaki Ozasa
Citations per year, relative to Hiroaki Ozasa Hiroaki Ozasa (= 1×) peers Chung-Tsen Hsueh

Countries citing papers authored by Hiroaki Ozasa

Since Specialization
Citations

This map shows the geographic impact of Hiroaki Ozasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Ozasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Ozasa more than expected).

Fields of papers citing papers by Hiroaki Ozasa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Ozasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Ozasa. The network helps show where Hiroaki Ozasa may publish in the future.

Co-authorship network of co-authors of Hiroaki Ozasa

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Ozasa. A scholar is included among the top collaborators of Hiroaki Ozasa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Ozasa. Hiroaki Ozasa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Murakami, Kosaku, Tomonori Yaguchi, Kenji Chamoto, et al.. (2025). ICOS+CD4+ T cells define a high susceptibility to anti–PD-1 therapy–induced lung pathogenesis. JCI Insight. 10(10). 1 indexed citations
2.
Yoshida, Hironori, Hiroshi Yoshida, Kazutaka Hosoya, et al.. (2025). Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study. BMC Cancer. 25(1). 388–388.
3.
Isobe, Kazutoshi, Yasuhiko Nakamura, Susumu Sakamoto, et al.. (2024). Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia. ERJ Open Research. 10(2). 981–2023. 4 indexed citations
4.
Ozasa, Hiroaki, Takahiro Tsuji, Tomoko Funazo, et al.. (2023). Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer. Molecular Cancer Therapeutics. 23(4). 564–576. 5 indexed citations
5.
6.
Ozasa, Hiroaki, Susumu Satô, Tomoko Funazo, et al.. (2021). Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer. Scientific Reports. 11(1). 23677–23677. 14 indexed citations
7.
Funazo, Tomoko, Takahiro Tsuji, Hiroaki Ozasa, et al.. (2020). Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Molecular Cancer Therapeutics. 19(6). 1320–1327. 5 indexed citations
8.
Tsuji, Takahiro, Hiroaki Ozasa, Wataru Aoki, et al.. (2018). Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Molecular Cancer Research. 17(1). 212–224. 41 indexed citations
9.
Yasuda, Yuto, Takashi Nomizo, Hiroaki Ozasa, et al.. (2017). Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Molecular and Clinical Oncology. 7(4). 677–680. 9 indexed citations
10.
Yoshida, Hironori, Young Hak Kim, Hiroaki Ozasa, et al.. (2016). Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Molecular and Clinical Oncology. 5(1). 213–215. 10 indexed citations
11.
Kim, Young Hak, Hiroaki Ozasa, Hiroki Nagai, et al.. (2013). High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib. Journal of Thoracic Oncology. 8(9). e85–e86. 35 indexed citations
12.
Uemura, Takehiro, Tetsuya Oguri, Hiroaki Ozasa, et al.. (2010). ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Science. 101(11). 2404–2410. 48 indexed citations
13.
Shimizu, Ryoichi, et al.. (2009). A Case of Small Bowel Obstruction Caused by Food in Plastic Wrap. 58(2). 67–71.
14.
15.
Ozasa, Hiroaki, Tetsuya Oguri, Takehiro Uemura, et al.. (2009). Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Science. 101(1). 161–166. 101 indexed citations
16.
Uemura, Takehiro, Hiroaki Ozasa, Tetsuya Oguri, et al.. (2008). MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small-cell lung cancer. Cancer Research. 68. 3240–3240. 5 indexed citations
17.
Oguri, Tetsuya, Hiroaki Ozasa, Takehiro Uemura, et al.. (2008). MRP7/ABCC10expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Molecular Cancer Therapeutics. 7(5). 1150–1155. 64 indexed citations
18.
19.
Ozasa, Hiroaki, et al.. (2006). Intrahepatic Biliary Stricture Caused by a Retrograde Transhepatic Biliary Drainage Tube: A Case Report. The Japanese Journal of Gastroenterological Surgery. 39(6). 672–676.
20.
Ozasa, Hiroaki, et al.. (2004). A Case of Hepatocellular Adenoma with Difficulty in Preoperative Diagnosis. 53(3). 165–171.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chung-Tsen Hsueh Breakdown of academic impact, for papers by Fraser Symmans Breakdown of academic impact, for papers by Ken Suzawa Breakdown of academic impact, for papers by Ichiro Kawada Breakdown of academic impact, for papers by Shigebumi Tanaka Breakdown of academic impact, for papers by Jianchun Duan Breakdown of academic impact, for papers by Judit Moldvay Breakdown of academic impact, for papers by Mark C. Markowski Breakdown of academic impact, for papers by Angela Listì Breakdown of academic impact, for papers by Jingyu Yu
Rankless by CCL
2026